U.S. markets closed

XpresSpa Group, Inc. (XSPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6200-0.0100 (-0.61%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close1.6300
Open1.6310
Bid1.6100 x 3000
Ask1.6200 x 3000
Day's Range1.5700 - 1.6700
52 Week Range1.0300 - 4.6700
Volume1,596,465
Avg. Volume2,776,087
Market Cap170.602M
Beta (5Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Where Do Hedge Funds Stand On XpresSpa Group, Inc. (XSPA)?
    Insider Monkey

    Where Do Hedge Funds Stand On XpresSpa Group, Inc. (XSPA)?

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

  • Strong Earnings Confirm the Bull Thesis on XpresSpa  Stock, Says Analyst
    TipRanks

    Strong Earnings Confirm the Bull Thesis on XpresSpa Stock, Says Analyst

    XpresSpa (XSPA) made an unlikely move during the pandemic and turned its shuttered airport wellness business into Covid-19 testing facilities. Looking at the company’s 1Q21 results, H.C. Wainwright’s Scott Buck thinks the move has paid off. The company delivered revenue of $8.5 million, way above Buck’s forecast for revenue of $2.4 million. “The beat to our estimate reflects better than expected revenue contribution from XpresCheck, which totaled $8.2M, though included $3.2M in revenue that was unable to be recognized in prior quarters.” The result of which was also a big mark up for store margin, which came in at 51.1%, far above Buck’s 14.5% estimate, and also much higher than the pre-pandemic store margins of 21% and 22% in 2018 and 2019, respectively. What this proves to Buck is that the company’s XpresCheck initiative – the Covid-19 testing facilities – is providing “proof of concept to investors who have been less than patient in awaiting results.” There’s other good news. The company saw out the quarter operating 13 XpresCheck locations in 11 airports, six of which opened during the quarter, which implies to Buck that the full revenue contribution from all 13 locations is still to come. Furthermore, at last, the company revealed its new travel, health, and wellness brand, Treat. By the end of June, the company will start to roll out the latest concept, which will include some medical services as well as retail and travel products and services, in three phases. While there will initially be only two physical locations, Buck believes these “could potentially find homes” in as many as 30 U.S. airports. The physical stores will go alongside a meaningful digital footprint, which could provide a big opportunity for future growth. As such, Buck recommends investors “accumulate a position in XSPA shares ahead of what we anticipate to be a meaningful improvement in operating results.” All in all, Buck reiterated a Buy rating on XSPA stock along with a $3.5 price target. The implication for investors? Upside of 167%. (To watch Buck’s track record, click here) Some companies fly under Wall Street’s radar and XpresSpa currently appears to be one such name. Buck says the quarter’s results are “likely to open some eyes,” but the 5-star analyst’s review is currently the only one on record. (See XSPA stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • 12 Undervalued Cyclical Stocks for 2021
    Insider Monkey

    12 Undervalued Cyclical Stocks for 2021

    In this article we will take a look at 12 undervalued cyclical stocks for 2021. You can skip our comprehensive analysis of these companies and go directly to the 5 Undervalued Cyclical Stocks for 2021. Businesses that rise and fall with the economic cycle have always baffled investors. These cyclical stocks tend to perform very […]